Solid Bio Crashes on Gene Therapy Data as Peer Sarepta Gains

(Bloomberg) -- Solid Biosciences Inc. shares were hammered in early trading after initial results from an early-stage trial for its Duchenne muscular dystrophy gene therapy showed minimal responses...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.